Literature DB >> 31902948

High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma.

Tingting Qian1,2, Longzhen Cui3,4, Yan Liu3,4, Zhiheng Cheng5, Liang Quan1,2, Tiansheng Zeng6, Wenhui Huang1,2, Yifeng Dai5, Jinghong Chen2, Ling Liu1, Jingqi Chen2, Ying Pang1, Guangsheng Wu7, Xu Ye1, Jinlong Shi8, Lin Fu9,10,11,12, Chaozeng Si13.   

Abstract

The prognosis role of CCT3 in MM and the possible pathways it involved were studied in our research. By analyzing ten independent datasets (including 48 healthy donors, 2220 MM, 73 MGUS, and 6 PCL), CCT3 was found to express higher in MM than healthy donors, and the expression level was gradually increased from MGUS, SMM, MM to PCL (all P < 0.01). By analyzing three independent datasets (GSE24080, GSE2658, and GSE4204), we found that CCT3 was a significant indicator of poor prognosis (all P < 0.01). KEGG and GSEA analysis showed that CCT3 expression was associated with JAK-STAT3 pathway, Hippo signaling pathway, and WNT signaling pathway. In addition, different expressed genes analysis revealed MYC, which was one of the downstream genes regulated by JAK-STAT3 pathway, was upregulated in MM. This confirms that JAK-STAT3 signaling pathway may promote the progress of disease which was regulated by CCT3 expression. Our study revealed that CCT3 may play a supporting role at the diagnosis of myeloid, and high expression of CCT3 suggested poor prognosis in MM. CCT3 expression may promote the progression of MM mainly by regulating MYC through JAK-STAT3 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31902948     DOI: 10.1038/s41397-019-0145-6

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  46 in total

1.  p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Francesca Cottini; Yoshihisa Nozawa; Hyuk-Soo Seo; Hiroto Ohguchi; Mehmet K Samur; Diana Cirstea; Naoya Mimura; Yoshikazu Iwasawa; Paul G Richardson; Nikhil C Munshi; Dharminder Chauhan; Walter Massefski; Teruhiro Utsugi; Sirano Dhe-Paganon; Kenneth C Anderson
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

2.  Chaperonin-containing T‑complex protein 1 subunit 8 promotes cell migration and invasion in human esophageal squamous cell carcinoma by regulating α-actin and β-tubulin expression.

Authors:  Xiaojing Yang; Hanru Ren; Yuhui Shao; Yi Sun; Lihua Zhang; Hongling Li; Xiulong Zhang; Xinmiao Yang; Weiwei Yu; Jie Fu
Journal:  Int J Oncol       Date:  2018-03-27       Impact factor: 5.650

Review 3.  Cell migration in tumors.

Authors:  Hideki Yamaguchi; Jeffrey Wyckoff; John Condeelis
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

4.  A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data.

Authors:  Terence C W Poon; Nathalie Wong; Paul B S Lai; Magnus Rattray; Philip J Johnson; Joseph J Y Sung
Journal:  Gastroenterology       Date:  2006-08-10       Impact factor: 22.682

5.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Authors:  Antonio Palumbo; Asher Chanan-Khan; Katja Weisel; Ajay K Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria V Mateos; Tomer M Mark; Ming Qi; Jordan Schecter; Himal Amin; Xiang Qin; William Deraedt; Tahamtan Ahmadi; Andrew Spencer; Pieter Sonneveld
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

6.  Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.

Authors:  Mu Hao; Meirong Zang; Erik Wendlandt; Yan Xu; Gang An; Dasen Gong; Fei Li; Fang Qi; Yanru Zhang; Ye Yang; Fenghuang Zhan; Lugui Qiu
Journal:  Int J Cancer       Date:  2014-09-19       Impact factor: 7.396

7.  JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.

Authors:  A G Solimando; A Brandl; K Mattenheimer; C Graf; M Ritz; A Ruckdeschel; T Stühmer; Z Mokhtari; M Rudelius; J Dotterweich; M Bittrich; V Desantis; R Ebert; P Trerotoli; M A Frassanito; A Rosenwald; A Vacca; H Einsele; F Jakob; A Beilhack
Journal:  Leukemia       Date:  2017-09-28       Impact factor: 11.528

8.  Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Authors:  S S Chavan; J He; R Tytarenko; S Deshpande; P Patel; M Bailey; C K Stein; O Stephens; N Weinhold; N Petty; D Steward; L Rasche; M Bauer; C Ashby; E Peterson; S Ali; J Ross; V A Miller; P Stephens; S Thanendrarajan; C Schinke; M Zangari; F van Rhee; B Barlogie; T I Mughal; F E Davies; G J Morgan; B A Walker
Journal:  Blood Cancer J       Date:  2017-02-24       Impact factor: 11.037

9.  Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma.

Authors:  Weilong Zhang; Yuansheng Lin; Xiaoni Liu; Xue He; Ye Zhang; Wei Fu; Zuozhen Yang; Ping Yang; Jing Wang; Kai Hu; Xiuru Zhang; Weiyou Liu; Xiaoliang Yuan; Hongmei Jing
Journal:  J Transl Med       Date:  2018-12-18       Impact factor: 5.531

10.  Inferring the perturbed microRNA regulatory networks in cancer using hierarchical gene co-expression signatures.

Authors:  Jin Gu; Zhenyu Xuan
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

View more
  8 in total

Review 1.  The TRiCky Business of Protein Folding in Health and Disease.

Authors:  Heba Ghozlan; Amanda Cox; Daniel Nierenberg; Stephen King; Annette R Khaled
Journal:  Front Cell Dev Biol       Date:  2022-05-05

Review 2.  Therapeutic Role of Carotenoids in Blood Cancer: Mechanistic Insights and Therapeutic Potential.

Authors:  Yaseen Hussain; Khalaf F Alsharif; Michael Aschner; Abdulrahman Theyab; Fazlullah Khan; Luciano Saso; Haroon Khan
Journal:  Nutrients       Date:  2022-05-06       Impact factor: 6.706

3.  TCP1 increases drug resistance in acute myeloid leukemia by suppressing autophagy via activating AKT/mTOR signaling.

Authors:  Xiaofang Chen; Xianling Chen; Yiping Huang; Jia Lin; Yong Wu; Yuanzhong Chen
Journal:  Cell Death Dis       Date:  2021-11-08       Impact factor: 8.469

4.  Chaperonin containing TCP1 subunit 3 (CCT3) promotes cisplatin resistance of lung adenocarcinoma cells through targeting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway.

Authors:  Xu Danni; Zeng Jiangzheng; Sun Huamao; Pan Yinglian; Yang Changcheng; Lu Yanda
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Low expression of TCP1 (T-Complex 1) and PSMC1 (Proteasome 26S subunit, ATPase 1) in heterotopic ossification during ankylosing spondylitis.

Authors:  Xiao-Lin Zhong; Bang-Ping Qian; Ji-Chen Huang; Shi-Zhou Zhao; Yao Li; Yong Qiu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 6.  Current understanding on the role of CCT3 in cancer research.

Authors:  Wenlou Liu; Yu Lu; Xiang Yan; Quansheng Lu; Yujin Sun; Xiao Wan; Yizhi Li; Jiaqin Zhao; Yuchen Li; Guan Jiang
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

7.  Suppression of CCT3 inhibits the proliferation and migration in breast cancer cells.

Authors:  Gang Xu; Shanshan Bu; Xiushen Wang; He Zhang; Hong Ge
Journal:  Cancer Cell Int       Date:  2020-06-05       Impact factor: 5.722

8.  Identification of CCT3 as a prognostic factor and correlates with cell survival and invasion of head and neck squamous cell carcinoma.

Authors:  Yan Wang; Peicheng Liu; Ziwei Zhang; Jiulong Wang; Zhigang Cheng; Chengchao Fan
Journal:  Biosci Rep       Date:  2021-10-29       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.